Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 482

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 4
Chunk 482
---
il
    Nanji Shekhat, M.D.
     
    44
     
    Director
  
    Edward
    MacPherson
     
    36
     
    Director

The
following is a brief biography of each of our current executive officers and directors:

Erez
Aminov has served as a director and our Chief Executive Officer since April 2023 and our Chairman since March 2024. Mr. Aminov
is an experienced biotechnology consultant and investor and initially joined our as a consultant in 2022. Mr. Aminov’s experience
in the biotech consulting sector began in 2021 when he founded Locate Venture Corp. in September 2021. Locate Venture is a strategy and
investment consulting firm focused on advancing and supporting early-stage biotech startups. Prior to founding Locate Venture Corp.,
from February 2015 to September 2020, Mr. Aminov served as the President of Finds4less Inc., a global distributor of electronics and
gaming products. In this role, Mr. Aminov provided strategic oversight and direction for all aspects of the company’s operations,
while also spearheading new business development initiatives to capitalize on emerging market opportunities. Mr. Aminov’s more
than two decades of experience includes experience with the biotech industry’s particular challenges, including creating strategic
alliances and guiding startups toward growth and prosperity. Mr. Aminov earned a B.A. in Accounting from Touro University in New York.
We believe that Mr. Aminov is qualified to serve as one of our directors based on his finance and investment experience, particularly
with early stage life sciences companies.

66

Michelle
Yanez, MBA has served as our Chief Financial Officer since April 2023, prior to which she served as our Corporate Controller
since May 2022. Ms. Yanez is a senior financial executive with over 25 years of experience in public and privately held biotech, pharmaceutical,
and life science companies. Ms. Yanez’ experience includes a broad range of responsibilities in a highly complex and regulated
market. She also brings deep corporate governance experience through her work with corporate boards, including audit and finance committees.
Since June 2024, Ms. Yanez also serves as Chief Financial Officer for Telomir Pharmaceuticals (Nasdaq: TELO), a pre-clinical-stage pharmaceutical
company, seeking to lead development in age-reversal science, by focusing on the development of a